Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.4.1 is now shown, replacing v3.4.0. No study content or eligibility criteria appear to be changed.SummaryDifference0.0%

- Check8 days agoChange DetectedThe changes add a Show glossary option and standardize metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These updates do not alter core study content, eligibility, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoChange DetectedAdded related topics: Ovarian cancer and MedlinePlus Genetics to the page.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded Revision: v3.3.4; removed related topics 'Ovarian cancer' and 'MedlinePlus Genetics', and removed 'Revision: v3.3.3'.SummaryDifference0.2%

- Check44 days agoChange DetectedNew Locations section added with Ohio and Wisconsin sites, replacing the previous separate Ohio Locations and Wisconsin Locations sections.SummaryDifference0.3%

- Check73 days agoChange DetectedAdded Revision: v3.3.2 to the revisions section. Deleted Revision: v3.2.0 from the revisions history.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.